Looking for Etanercept found 19 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Etanercept
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Etanercept
(Enbrel®, Benapali® & Erelzi®)
|
Skin - Drugs affecting the immune response - 13.05.03
|
| |
Anakinra
(Kineret®)
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Infliximab
(Remsima®, Inflectra®, Remicade® )
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Tocilizumab
(RoActemra®)
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Links Link to Drug Section  Link to document |
|
NICE TA103: Psoriasis - efalizumab and etanercept (13.05.03)
|
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
|
